Keros Therapeutics Presents Preclinical And Clinical Data From Its KER-012 Program At The American Thoracic Society International Conference
Portfolio Pulse from Benzinga Newsdesk
Keros Therapeutics presented clinical and preclinical data from its KER-012 program at the American Thoracic Society International Conference. The data showed potential for KER-012 to treat fibrosis and inflammation in patients with pulmonary arterial hypertension and cardiovascular disease.
May 22, 2023 | 1:28 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Keros Therapeutics presented positive clinical and preclinical data for its KER-012 program, which may lead to increased interest in the company's stock.
Keros Therapeutics presented clinical and preclinical data from its KER-012 program at the American Thoracic Society International Conference. The data showed potential for KER-012 to treat fibrosis and inflammation in patients with pulmonary arterial hypertension and cardiovascular disease. This positive news may lead to increased interest in the company's stock and potential short-term gains.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100